drugset
drugset / Trial / NCT07695597

A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia

NCT07695597 ↗

Phase 2 Not yet recruiting 240 enrolled CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.

Timeline

Start
2026-07-17
Primary completion
2027-04-30
Completion
2027-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SYH2070 Unknown 150 mg —
Subject SYH2070 Unknown 300 mg —
Subject SYH2070 Unknown 400 mg —

Indications

hyperlipidemia, combined, 2